FindTrial
Sign In

Half effective dose of remazolam combined with afentanil in the rapid reversible induction of general anesthesia under the wrist and ankle needle

Half effective dose of remazolam combined with afentanil in the rapid reversible induction of general anesthesia under the wrist and ankle needle

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300067371
Enrollment
Unknown
Registered
2023-01-05
Start date
2023-01-16
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Study on induction drugs of general anesthesia

Interventions

Group 1:Female group 18~65 years old: Stage I: wrist and ankle acupuncture + 0.3 mg/kg Remazolam + Afentanil (modified sequential administration) Phase II: wrist and ankle needle + Remazolam (modifi
Group 2:Male group aged 18~65 years: Phase I: wrist ankle acupuncture + 0.3 mg/kg remidazolam + alfentanil (modified sequential administration) Phase II: wrist ankle acupuncture + remidazolam (modifie
Group 3:Women >= 65 years old: Stage I: wrist and ankle needle + 0.3 mg/kg Remazolam + Afentanil (modified sequential administration) Phase II: wrist and ankle needle + Remazolam (modified sequential
Group 4:Male group >= 65 years old: Stage I: wrist ankle needle + 0.3 mg/kg Remazolam + Afentanil (modified sequential administration) Phase II: wrist and ankle needle + Remazolam (modified sequenti

Sponsors

Hebei Provincial Hospital of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1. Patients undergoing general anesthesia, regardless of gender; 2. Age >= 18 years old; good cardiopulmonary function, in line with ASA (American Society of Anesthesiologists) standards I-III, without other serious systemic diseases; 3. The patient has no acupuncture experience; 4. Those who voluntarily participate in this study and sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Those who have other serious systemic comorbidities or mental disorders or those who cannot cooperate for other reasons; 2. Breast-feeding and pregnant women; 3. Allergic constitution and long-term use of hormone drugs; 4. Non-voluntary participants in this experiment; 5. Taking psychotropic drugs.

Design outcomes

Primary

MeasureTime frame
ED50,ED95 of Afentanil during rapid reversible induction of general anesthesia;ED50, ED95 of remimazolam during rapid reversible general anesthesia induction;—

Secondary

MeasureTime frame
From the start of administration to the time when the patient loses consciousness.;the changes of BIS values;Dose of remedial sedative;—

Countries

China

Contacts

Public ContactHao Wei

Hebei Provincial Hospital of Traditional Chinese Medicine

keyan_66666@126.com+86 138 3212 2359

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026